Generics Overview in the Seven Major Markets

Increasing generics volume uptake will provide much needed cost-savings in the less mature markets of France, Italy, Spain, and Japan, and requires regulators to incorporate effective utilization incentives for key stakeholders. While volume will grow in the US, Germany, and the UK, regulators are increasingly looking to capture value from generics by pushing down price and speeding market access.

The mature generics markets of the US, Germany, and the UK, are the largest of the seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan), and also show the highest levels of generic volume uptake. Indeed, erosion is greatest and most rapid in the largest generics market, the US.

The industry continues to face considerable barriers to uptake in the less mature markets of France, Italy, Spain, and Japan, with the absence of effective incentives the key issue. Conversely, pricing and regulatory pressures in the more mature generics markets act to drive down the value of these markets.

Competitive pressures across the seven major markets have intensified to the extent that the operating margin of the leading generics companies has declined between 2002 and 2008, while that of companies with a historical emerging market focus has changed little.

Read more...

• Jacobsen Pharma A/S (20/07/2010)
• Depression (28/06/2010)
• Company Outlook (15/01/2010)

• PACS Market (14/01/2010)
• US Surgical Sutures Market (14/01/2010)
• Pharma M&A Landscape (16/12/2009)
• Colorectal Cancer (07/12/2009)
• Multi-Marketing (03/12/2009)
• Generic Strategies (03/12/2009)
• Vaccines in Emerging Markets (13/11/2009)
• Influenza Vaccines and Antivirals (13/11/2009)
• Diabetes Market (30/10/2009)

---